Dr. Reddy’s Laboratories Ltd ADR annual revenue for fiscal TTM was ₹332.8 billion, a decrease of 5.8% from ₹353.5 billion in fiscal 2026. All figures are reported results from public filings — no estimates or projections.
| Revenue (annual) | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 | 2017-03-31 | 2016-03-31 | 2015-03-31 | 2014-03-31 | 2013-03-31 | 2012-03-31 | 2011-03-31 | 2010-03-31 | 2009-03-31 | 2008-03-31 | 2007-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ₹332.8B | ₹353.5B | ₹325.5B | ₹279.2B | ₹245.9B | ₹214.4B | ₹2.6B | ₹174.6B | ₹153.9B | ₹142.0B | ₹140.8B | ₹154.7B | ₹148.2B | ₹132.2B | ₹116.3B | ₹96.7B | ₹74.7B | ₹70.3B | ₹69.4B | ₹50.0B | ₹65.2B |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Revenue (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | ₹81.2B | ₹76.3B | ₹87.3B | ₹88.1B | ₹85.5B | ₹85.1B | ₹83.6B | ₹80.2B |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More RDY metrics: Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All RDY financial statements → Interactive RDY charts →
About TickerBase · Data methodology & sources · Privacy · Terms